Health
Why Might Cassava Succeed With Its Alzheimer’s Drug, When So Many Have Failed? – The Motley Fool
Alzheimer’s research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about…
Cassava Sciences(NASDAQ:SAVA) is like any other unprofitable biotech — it has a drug in clinical trials, and its investors are hoping the drug works so they can make a lot of money. What makes Cassava really interesting is that it’s zigging where Big Pharma…
Continue Reading
-
Business24 hours agoUS markets swung wildly last night. How extreme volatility can be a gift to ASX investors
-
Noosa News23 hours agoMajor flood arrives at Birdsville
-
Business8 hours agoHow I’d build a $100,000 ASX portfolio from scratch
-
Noosa News22 hours agoPolice officer charged, North Coast Region